The Non-Negotiable Standard in Clinical Trials
In 2026, global regulators will require RBQM in every stage of clinical trials.
In 2026, global regulators will require RBQM in every stage of clinical trials.
Discover how proportionality of risk prioritises what truly matters to protect patients and ensure data integrity.
Discover how proportionality of risk prioritises what truly matters to protect patients and ensure data integrity.
As sponsors adapt to ICH R3, we explore whether sites are getting the support they need to keep up.
QbD is the most effective way to protect participants and data in clinical trials, yet the industry still struggles to make it a priority.
TRI’s GCP e-learning module turns ICH E6(R3) principles into practical, scenario-based training.
Risk-based approaches are everyone’s top priority in clinical trials, but no one seems to have a clear playbook.
TRI CEO Duncan Hall will be at Scope Europe 2025, sharing how technology is meeting the evolving needs of RBQM.
Despite high awareness, ICH E6(R3) adoption is stalling, only 19% of organizations report significant change.